A strategy for stroke by Brown, MM
Professor Martin M Brown describes the circumstances that led him to dedicate his career  
to stroke research and reveals the ways in which understanding of the condition is changing
Why did you initially pursue a research interest 
in stroke?
As a Senior House Officer at the Hammersmith 
Hospital, UK, in 1976, I worked for Professor Jack 
Shillingford on the coronary care unit (CCU). 
This had been one of the first of its kind in the 
world, with the aim of researching ways to 
improve the care of patients with myocardial 
infarction. Patients were rushed by ambulance 
directly to the CCU, where they were monitored 
and treated intensively. It struck me at the time 
how extraordinary it was that patients arriving at 
the hospital with cerebral thrombosis, a similar 
problem but in the brain, were virtually ignored. 
It was then that I resolved to specialise in stroke 
and decided that what was needed to advance 
stroke care was acute stroke units and research 
into stroke treatment. It was more than 30 years 
before the UK’s National Health Service (NHS) 
finally accepted the need for acute emergency 
admission of stroke patients to hyperacute 
stroke units.
How have treatment strategies for stroke 
developed in recent years? 
In addition to the major advances in service 
provision, there have been extraordinary 
changes in the management of acute stroke 
in the last few years, firstly with the advent of 
early aspirin therapy, then the introduction of 
intravenous thrombolysis and, more recently, 
the development of endovascular techniques 
for thrombus extraction from cerebral arteries. 
Prevention therapies have evolved from relying 
on aspirin and less-than-satisfactory control of 
hypertension to current regimes of intensive 
therapy with dual antiplatelet therapy, targeted 
blood pressure lowering and statin therapy to 
lower cholesterol. It is likely that the introduction 
of statins and their widespread use has had the 
greatest therapeutic impact on stroke rates, 
although improved screening for hypertension, 
reduction in smoking, healthier diets and higher 
standards of living have had an equally important 
impact in the community. 
Are there suitable models that can be used to 
predict a patient’s stroke risk?
Although a very large number of risk factors have 
been identified, very few modelling studies have 
attempted to predict an individual’s future risk 
of stroke. One exception is the Oxford Stroke 
Prevention Research Unit tool for predicting 
the risk of stroke in patients with recently 
symptomatic carotid artery stenosis, but this 
uses data from trials of carotid stroke treatments 
conducted more than 20 years ago, and therefore 
needs to be updated. Furthermore, existing risk 
calculation tools such as the Framingham Risk 
Score take into account too few risk factors to be 
sufficiently reliable.
Stroke research receives significantly less 
funding than other major illnesses, such as 
cancer and heart disease, despite its high 
levels of morbidity and mortality. Why is this, 
and how can this be changed?
The reasons why stroke research has received 
significantly less funding are complex. One 
reason may be the outdated perception that 
there is no treatment for stroke, which of 
course is no longer true. Another reason 
may be that it is seen as a disease of the 
elderly, which again is not true; strokes 
can occur at any age, and indeed 25 per 
cent of stroke patients are under the 
age of 65. A third reason may be the 
fact that stroke is not seen as a painful 
condition, and perhaps the fear of pain 
from heart attack and cancer influences 
individuals’ charitable donations. 
There is a lot of ignorance about stroke, 
which could no doubt be changed by 
government initiatives and pressure 
groups; for example, the Stroke Association 
had considerable success in persuading the 
UK Government to improve stroke services 
through the National Stroke Strategy. However, 
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the Stroke Association still remains vastly 
underfunded compared to the cancer and heart 
disease charities, which means its ability to 
influence external funding and fund research 
and new posts is very limited, compounding the 
inequality in provision. 
What would you consider to be your greatest 
professional achievement to date?
On the clinical side, developing three acute 
stroke units in three hospitals over 20 years, 
each of which improved on the previous one. 
On the educational side, establishing stroke 
medicine as an officially recognised sub-
specialty with a specialist training programme 
and curriculum. On the research side, 
organising and completing the 
International Carotid Stenting 
Study. That said, although I may 
have had the ideas that led 
to these initiatives, none 
of it would have been 
possible without 
the support and 
hard work of 
many others.
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Treating carotid atherosclerosis
Since the 1990s, Professor Martin M Brown of the University College 
London Institute of Neurology has been leading international, 
multicentre clinical trials to establish suitable treatments for 
reducing stroke risk in individuals with carotid artery stenosis
STROKE IS THE largest cause of adult disability 
and third largest cause of death in the UK and 
yet, when compared to other major illnesses 
such as cancer and heart disease, research into 
stroke is significantly underfunded. Many myths 
have historically surrounded strokes; that little 
can be done to prevent them, for example, or 
that their effects are limited to the elderly. It 
was because of this state of affairs that, over 
three decades ago, a young Martin M Brown 
decided to devote his career to improving stroke 
outcomes for patients. Now Professor of Stroke 
Medicine at the University College London 
(UCL) Institute of Neurology, Brown has seen 
considerable improvements since his early days 
in healthcare. However, much work remains to 
be done if stroke mortality and morbidity rates 
are to be reduced still further.
CAROTID CARE
20 per cent of strokes are caused by narrowing 
(stenosis) of the internal carotid artery, which 
supplies the eyes and brain with oxygenated 
blood; this therefore constitutes a major subset 
of stroke cases. In 1988 Brown joined the North 
American Symptomatic Carotid Endarterectomy 
Trial (NASCET) in Canada as a neurological 
coordinator: “This stimulated my interest in both 
carotid disease and clinical trials,” he reveals. 
Upon returning to the UK, Brown obtained a grant 
to further investigate this area – and thus the 
Carotid and Vertebral Transluminal Angioplasty 
Study (CAVATAS) was born.
The first international, multicentre trial to 
investigate endovascular treatment of carotid 
stenosis, from 1992-97 CAVATAS recruited over 
500 carotid artery stenosis patients. Following 
its subjects for up to 11 years, the ultimate aim 
was to compare the long-term outcomes for 
patients given endovascular treatment by carotid 
angioplasty or stenting against conventional 
endarterectomy (carotid surgery). A number 
of interesting results emerged, including the 
finding that, although there was no significant 
difference in the rates of major stroke, restenosis 
(re-narrowing of the arteries) was more likely 
to occur following endovascular rather than 
surgical treatment. The results of the trial had 
a significant impact on medical guidelines 
and practices. However, the findings were not 
ultimately definitive because the stroke rates in 
the trial were considered too high and because 
the study became outdated after angioplasty 
was completely replaced as a technique by 
carotid stenting.
SEARCHING FOR ANSWERS
Faced with wide confidence intervals and 
a clear need for additional long-term data, 
Brown decided to remedy the situation with a 
second international, multicentre project: the 
International Carotid Stenting Study (ICSS). 
This randomised clinical trial sought to establish 
the effectiveness of stenting compared to 
endarterectomy by following 1,700 participants 
across 50 centres spanning Europe, Canada, 
Australia and New Zealand over the course of a 
decade, from 2001 onwards.
This time round, the project produced some 
definitive results, including the finding that the 
risks associated with carotid stenting and surgery 
were not as high as CAVATAS had indicated. 
Although stenting posed an increased risk of 
minor stroke during the insertion procedure as 
opposed to surgery, it also avoided the potential 
dangers associated with carotid endarterectomy, 
such as cranial nerve injury. Overall, long-term 
disability, quality of life, and mortality did not 
differ significantly between the two treatments. 
There was also no difference in cost-effectiveness. 
This led the ICSS researchers to call for greater 
awareness of the potential risks and benefits of 
each treatment for an individual patient. “The 
data from ICSS show that stenting can be offered 
to patients as an alternative to endarterectomy, 
so long as there are features suggesting that the 
risk of procedural stroke with stenting is likely to 
be similar or lower than that of endarterectomy,” 
explains Brown.
LOOK A LITTLE CLOSER
One way in which the risk of stenting versus 
endarterectomy for an individual patient can be 
established is through the use of brain scans to 
assess existing damage. An ICSS sub-study found 
that patients with above-average cerebral white 
matter damage were more at risk during stenting, 
while for those with lesser damage, there was no 
difference in risk. This suggests that brain scans 
hold significant promise when it comes to helping 
physicians and patients make informed decisions 
about the most suitable treatment options.
Indeed, this is something that Brown is 
investigating further: “We have been particularly 
interested in using magnetic resonance imaging 
(MRI) of the brain as a follow-up tool,” he outlines. 
This is because recent evidence has indicated that 
MRI is effective at detecting cerebral infarction, 
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sensitive to microscopic haemorrhages 
(microbleeds), and may even be able to predict 
future risk of vascular events.
BETTER TOGETHER
In order to maximise the findings of trials such 
as ICSS, Brown set up the Carotid Stenting 
Triallists Collaboration in 2009, together with 
colleagues from Germany and France, with the 
aim of progressing stroke research and pooling 
data. It was through this joint initiative that the 
Collaboration was able to combine ICSS findings 
with data from two other major European 
trials – the Endarterectomy Versus Angioplasty 
in patients with Symptomatic Severe carotid 
Stenosis trial (EVA-3S) and the Stent-Protected 
Angioplasty versus Carotid Endarterectomy in 
symptomatic patients trial (SPACE). 
The Carotid Stenting Triallists Collaboration 
analysis brought to light an additional factor that 
may be used to predict an individual’s stenting 
risk: age. It was found that, for patients over the 
age of 70, stenting posed a significantly higher 
risk than endarterectomy, whereas for patients 
under 70 the difference in risk was insignificant. 
Indeed the younger the patient, the greater the 
potential benefits of stenting over surgery. 
This finding has been supported by findings from 
the North American Carotid Revascularization 
Endarterectomy versus Stenting Trial (CREST), 
which joined the Carotid Stenting Triallists 
Collaboration (now know as the Carotid 
Stenosis Triallists Collaboration) at a later 
stage. “On the whole, it is remarkable how 
consistent the results of the four trials included 
in the Carotid Stenosis Triallists Collaboration 
have been,” Brown comments. 
PAVING THE WAY FOR 
PERSONALISED TREATMENT
Being able to accurately calculate the stroke 
risk of an individual with carotid artery 
stenosis holds clear benefits; at present, 
five-year risk can range from 5-40 per cent. 
For over a quarter of a century, stroke risk 
for carotid artery stenosis patients has been 
predicted using a model developed by the 
Oxford Stroke Prevention Unit. Given that 
this method does not take into account the 
significant developments that have taken 
place in stroke medicine in the past 25 years, 
the prediction strategy is clearly in need of 
revision to improve its accuracy. 
This is where Brown’s current project, the 
Second European Carotid Surgery Trial (ECST-
2), comes in. “We will be testing a revised 
version of the risk model,” Brown reveals. 
This new trial will make use of novel imaging 
techniques to reveal the composition of 
the carotid plaque, which Brown expects to 
accurately predict five-year stroke risk. The 
plan is to develop an even more accurate risk 
model so that such scores can ultimately be 
used when deciding how best to treat a carotid 
artery stenosis patient. 
In terms of determining a patient’s treatment 
options, ESCT-2 also aims to establish 
the benefits of optimised medical therapy 
compared with carotid endarterectomy. 
Brown predicts that such research is essential 
for the development of innovative, effective 
stroke therapies. In the future, the hope is that 
clinicians will have the knowledge and capacity 
to offer patients with carotid artery stenosis 
the best courses of treatment for the individual.
CAROTID ANGIOPLASTY
A small balloon is temporarily inserted into the affected artery and then 
expanded, thus opening up the artery and restoring a healthy flow of blood
 
STENTING
A small metal mesh tube, or ‘stent’, is placed within the artery to hold the 
artery wide open
 
ENDARTERECTOMY
A surgical procedure to remove plaque from the artery walls via a small 
incision in the neck to reach the narrowed section of the artery
 
OPTIMISED MEDICAL TREATMENT 
Medical therapy adjusted to achieve individualised optimum levels of 
blood pressure and serum cholesterol levels, combined with targeted 
lifestyle modifications and antiplatelet therapy
Carotid comparisons
Over the course of the clinical trials he has overseen, Professor 
Martin Brown has endeavoured to establish the best of four major 
treatments for carotid artery stenosis:
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